Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Language
Publication year range
1.
J Neurosci Methods ; 366: 109412, 2022 Jan 15.
Article in English | MEDLINE | ID: mdl-34798213

ABSTRACT

BACKGROUND: The effects of tobacco smoke on the central nervous system are usually studied with isolated nicotine, ignoring other compounds present in cigarette smoke. The few studies that use in vivo whole-body cigarette smoke exposure are usually performed in expensive commercial apparatus. NEW METHOD: We presented a feasible, safe, and low-cost apparatus for cigarette smoke exposure in rodents. RESULTS: Rats exposed to cigarette smoke in this apparatus showed cotinine levels similar to human active smokers. Additional results showed that cigarette smoke exposure increased glutamate and aspartic acid levels and decreased leucine, isoleucine, ornithine, phenylalanine, and tryptophan levels in the cerebrospinal fluid of rats. COMPARISON WITH EXISTING METHOD(S): Our apparatus is feasible, safe, and costs 67-fold less than a commercial automatized smoking machine. Beyond the low cost, it does not require specialized knowledge for building or maintenance. CONCLUSIONS: We concluded that our low-cost apparatus is reliable and reproduces cigarette smoke use in humans.


Subject(s)
Cigarette Smoking , Animals , Cotinine , Nicotine , Rats , Nicotiana
2.
Acta amaz ; 52(1): 53-59, 2022. ilus, graf, tab
Article in English | VETINDEX | ID: biblio-1437374

ABSTRACT

Copaiba oleoresin, extracted from the Copaifera reticulata tree, has been used as a remedy in popular medicine in the Brazilian Amazon for various purposes, including reducing drug abuse. Yet no studies evaluated the effect of repeated administration of copaiba oil on alcohol consumption in animals. To evaluate this effect, we divided adult male Wistar rats into a) an alcohol group in which the animals had free access to choose between two bottles: one containing alcohol solution (20%) and another containing vehicle solution (0.2% saccharin); and b) a control group with access to two bottles containing vehicle solution. Rats were free to drink 24 h per day, for 35 days. Daily alcohol consumption and weekly body weight gain and food intake were monitored. From day 22, half of the rats in each group received 600 mg kg-1 copaiba oleoresin and the other received vehicle, subcutaneously, once a day, for three days. On day 35, rats were evaluated in an open-field test. The results showed that copaiba oil decreased voluntary alcohol intake and preference between days 2 and 6 after the last administration. Copaiba treatment also decreased the food intake and body weight gain in both alcohol and control groups without changing behaviors in the open-field test. Therefore, copaiba oil was able to reduce voluntary alcohol consumption in rats and could be tested in humans as an adjuvant to treat alcohol use disorder.(AU)


O óleo extraído da árvore copaíba, Copaifera reticulata, tem sido usado na medicina popular na Amazônia brasileira para diversos fins, incluindo abuso de drogas. Contudo, não há estudos avaliando o efeito da administração repetida do óleo de copaíba sobre o consumo de álcool em animais. Para avaliar esse efeito, dividimos ratos Wistar machos adultos em dois grupos: a) um grupo álcool, no qual os animais tinham livre acesso a duas garrafas: uma contendo solução alcoólica (20%) e outra contendo solução veículo (sacarina 0,2%); e b) um grupo controle com acesso a duas garrafas contendo solução veículo. Os ratos podiam beber livremente, 24 horas por dia, durante 35 dias. O consumo diário de álcool, bem como o ganho de peso corporal semanal e a ingestão de alimentos foram monitorados. A partir do dia 22, metade dos ratos de cada grupo recebeu 600 mg kg-1 de óleo de copaíba e a outra metade recebeu veículo, por via subcutânea, uma vez ao dia, durante três dias. No dia 35, os ratos foram testados em teste de campo aberto. Os resultados mostraram que o óleo de copaíba diminuiu a ingestão voluntária e a preferência por álcool entre os dias 2 e 6 após a última administração. O tratamento com óleo de copaíba também diminuiu a ingestão alimentar e o ganho de peso corporal em ambos os grupos álcool e controle, sem alterar o comportamento no teste de campo aberto. Portanto, o óleo de copaíba foi capaz de reduzir o consumo voluntário de álcool em ratos e poderia ser testado em humanos como um adjuvante para tratar transtorno de uso de álcool.(AU)


Subject(s)
Animals , Rats , Alcohol Drinking/adverse effects , Oils, Volatile , Biological Products , Fabaceae/chemistry
3.
Behav Brain Res ; 380: 112444, 2020 02 17.
Article in English | MEDLINE | ID: mdl-31866463

ABSTRACT

Interactions on neurotransmitter systems in the reward pathways may explain the high frequency of combined use of alcohol and cigarettes in humans. In this study, we evaluated some behavioral and neurochemical changes promoted by chronic exposure to alcohol and cigarette smoke in rats. Adult rats were administered with 2 g/kg alcohol (v.o.) or/and inhaled the smoke from 6 cigarettes, twice/day, for 30 days. Behavioral tests were performed 3 h after the alcohol administration and 1 h after the last exposure to cigarette smoke in the morning. Cerebrospinal fluid was collected for glutamate determination and the hippocampus was dissected for GABAA and NMDA receptor subunits mRNA expression determination. Results showed that the combined use of alcohol and cigarette smoke (ALTB) in rats increased the locomotor activity and all interventions decreased anxiety-like behaviors. Despite being on a short-term withdrawal, the cigarette smoke exposure decreased the percentage of open arm entries in the elevated plus maze test, which was prevented by combined use with alcohol. Even though GABAA and glutamate receptor subunits expression did not change in the hippocampus, glutamate levels were significantly higher in the cerebrospinal fluid from ALTB rats. Therefore, we showed that the combined use of alcohol and cigarette maintained a psychostimulant effect after a short-term withdrawal that was associated with the elevated glutamatergic activity. The combined use also prevented anxiety-like signs in cigarette smoke exposure rats, decreasing an adverse effect caused by nicotine withdrawal. These results could explain, in part, the elevated frequency of combined use of these two drugs of abuse in humans.


Subject(s)
Anxiety/drug therapy , Behavior, Animal/drug effects , Central Nervous System Depressants/pharmacology , Cigarette Smoking , Ethanol/pharmacology , Glutamic Acid/cerebrospinal fluid , Hippocampus/drug effects , Hippocampus/metabolism , Locomotion/drug effects , Receptors, GABA-A/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Animals , Central Nervous System Depressants/administration & dosage , Drug Therapy, Combination , Ethanol/administration & dosage , Glutamic Acid/drug effects , Maze Learning , RNA, Messenger , Rats , Rats, Wistar , Receptors, GABA-A/drug effects , Receptors, N-Methyl-D-Aspartate/drug effects
4.
Amino Acids ; 50(1): 95-104, 2018 01.
Article in English | MEDLINE | ID: mdl-28936709

ABSTRACT

Diabetes is a chronic metabolic disease associated with oxidative stress, damage to biomolecules such as DNA, and neuroinflammation. Taurine, a sulfur-containing amino acid widespread in the brain, has neuroprotective properties that might prevent tissue injury and DNA damage induced by chronic hyperglycemia. We evaluated the effects of chronic taurine treatment on oxidative stress parameters, DNA damage and inflammatory markers in the frontal cortex, and hippocampus of streptozotocin-induced diabetic rats. Diabetic rats displayed increased levels of reactive oxygen species (ROS) and DNA damage in both areas, evidencing the pro-oxidant effects of diabetes in the brain. Moreover, this condition increased levels of several inflammatory mediators, such as IL-6, IL-12, TNF-γ, and IFN-α, more pronouncedly in the hippocampus. Supporting our hypothesis, taurine treatment reduced ROS, DNA damage, and inflammatory cytokine levels, providing evidence of its beneficial effects against genotoxicity and neuroinflammation associated with diabetes. Our data endorse the necessary clinical trials to evaluate the efficacy and safety of taurine supplementation in the prevention and treatment of neurochemical and metabolic alterations related to diabetes.


Subject(s)
Brain/drug effects , Diabetes Mellitus, Experimental/drug therapy , Oxidative Stress/drug effects , Taurine/pharmacology , Animals , Antioxidants/metabolism , Brain/metabolism , Brain/pathology , Cytokines/analysis , DNA Damage/drug effects , Diabetes Mellitus, Experimental/pathology , Male , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Taurine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL